Philip Johnson
Chief Executive Officer bei ARMO BIOSCIENCES INC
Vermögen: 3 Mio $ am 31.03.2024
Aktive Positionen von Philip Johnson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| DERMIRA, INC. | Director/Board Member | 20.02.2020 | - |
| ARMO BIOSCIENCES INC | Chief Executive Officer | 21.06.2018 | - |
| DICE THER | President | 09.08.2023 | - |
| Director/Board Member | 09.08.2023 | - | |
| SIGILON THERAPEUTICS, INC. | Director/Board Member | 11.08.2023 | - |
| President | 11.08.2023 | - | |
| POIT BIOP | Director-Back Office Operation | 27.12.2023 | - |
| President | 27.12.2023 | - | |
| JAZZ PHARMACEUTICALS PLC | Director of Finance/CFO | 01.03.2024 | - |
The American Chamber of Commerce in Japan
 The American Chamber of Commerce in Japan Miscellaneous Commercial ServicesCommercial Services The American Chamber of Commerce in Japan is a Chamber of Commerce. The non-profit company is based in Minato-ku, Japan. | Director/Board Member | - | - |
Karriereverlauf von Philip Johnson
Ehemalige bekannte Positionen von Philip Johnson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ELI LILLY AND COMPANY | Investor Relations Contact | - | 01.01.2018 |
| Treasurer | 01.01.2018 | 29.02.2024 | |
| AKOUOS | Director/Board Member | 01.12.2022 | - |
| President | 01.12.2022 | - | |
| ░░░ ░░░░░ ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░░░ | - | - |
Ausbildung von Philip Johnson
| Northwestern University | Graduate Degree |
| University of Illinois | Undergraduate Degree |
| Lund University School of Economics & Management | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 10 |
| Japan | 2 |
| Italien | 2 |
Operativ
| Director/Board Member | 5 |
| President | 5 |
| Chief Executive Officer | 2 |
Sektoral
| Health Technology | 10 |
| Consumer Services | 4 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| SIGILON THERAPEUTICS, INC. | Health Technology |
| POIT BIOP | Health Technology |
| Private Unternehmen | 6 |
|---|---|
The American Chamber of Commerce in Japan
The American Chamber of Commerce in Japan Miscellaneous Commercial ServicesCommercial Services The American Chamber of Commerce in Japan is a Chamber of Commerce. The non-profit company is based in Minato-ku, Japan. | Commercial Services |
Eli Lilly Italia SpA
 Eli Lilly Italia SpA Pharmaceuticals: MajorHealth Technology Eli Lilly Italia SpA manufactures pharmaceutical products. The company was founded by Colonel Eli Lilly in 1876 and is headquartered in Sesto Fiorentino, Italy. | Health Technology |
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
ARMO BioSciences, Inc.
 ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA. | Health Technology |
DICE Therapeutics, Inc.
 DICE Therapeutics, Inc. BiotechnologyHealth Technology DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA. | Health Technology |
Akouos, Inc.
 Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Philip Johnson
- Erfahrung
